SC 13G

NAME OF REPORTING PERSONS

GV 2017, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SC 13G 1 d489212dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Verve Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

92539P101

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐	Rule 13d-1(b)

☐	Rule 13d-1(c)

☒	Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

Page 1 of 19


CUSIP No. 92539P101		13G

⁽¹⁾

Consists of 6,320,905 shares of the Issuer’s Common Stock held directly by GV 2017, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2017, L.P.

⁽²⁾

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 2 of 19


CUSIP No. 92539P101		13G

⁽¹⁾

⁽²⁾

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 3 of 19


CUSIP No. 92539P101		13G

⁽¹⁾

⁽²⁾

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 4 of 19


CUSIP No. 92539P101		13G

⁽⁴⁾

Consists of 4,472,509 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P.

⁽⁵⁾

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 5 of 19


CUSIP No. 92539P101		13G

⁽⁴⁾

⁽⁵⁾

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 6 of 19


CUSIP No. 92539P101		13G

⁽⁴⁾

⁽⁵⁾

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 7 of 19


CUSIP No. 92539P101		13G

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 8 of 19


CUSIP No. 92539P101		13G

⁽⁶⁾

Consists of 6,320,905 shares of the Issuer’s Common Stock held directly by GV 2017, L.P. and 4,472,509 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2017, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P.

⁽⁷⁾

Consists of 6,320,905shares of the Issuer’s Common Stock held directly by GV 2017, L.P. and 4,472,509 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2017, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P.

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 9 of 19


CUSIP No. 92539P101		13G

⁽⁸⁾

Consists of 6,320,905 shares of the Issuer’s Common Stock held directly by GV 2017, L.P., 4,472,509 shares of the Issuer’s Common Stock held directly by GV 2019, L.P., and 180,597 shares of the Issuer’s Common Stock held directly by Verily Life Sciences LLC. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2017, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P. XXVI Holdings Inc. (the managing member of Verily Life Sciences LLC) and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may be deemed to have sole power to vote the shares held directly by Verily Life Sciences LLC.

⁽⁹⁾

Consists of 6,320,905 shares of the Issuer’s Common Stock held directly by GV 2017, L.P., 4,472,509 shares of the Issuer’s Common Stock held directly by GV 2019, L.P., and 180,597 shares of the Issuer’s Common Stock held directly by Verily Life Sciences LLC. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2017, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P. XXVI Holdings Inc. (the managing member of Verily Life Sciences LLC) and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may be deemed to have sole power to dispose of the shares held directly by Verily Life Sciences LLC.

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 10 of 19


CUSIP No. 92539P101		13G

⁽⁸⁾

⁽⁹⁾

Consists of 6,320,905 shares of the Issuer’s Common Stock held directly by GV 2017, L.P., 4,472,509 shares of the Issuer’s Common Stock held directly by GV 2019, L.P., and 180,597 shares of the Issuer’s Common Stock held directly by Verily Life Sciences LLC. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2017, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P. XXVI Holdings Inc. (the managing member of Verily Life Sciences LLC) and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may be deemed to have sole power to dispose of the shares held directly by Verily Life Sciences LLC.

⁽³⁾	Based on 48,171,010 shares of the Issuer’s Common Stock outstanding as of November 8, 2021 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

Page 11 of 19

ITEM 1(A).

NAME OF ISSUER

Verve Therapeutics, Inc.

ITEM 1(B).

ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

500 Technology Square, Suite 901

Cambridge, MA 02129

ITEM 2(A).

NAME OF PERSONS FILING:

This statement is filed by the following entities, collectively referred to as the “Reporting Persons”:

•

GV 2017, L.P., a Delaware limited partnership

•

GV 2017 GP, L.P., a Delaware limited partnership

•

GV 2017 GP, L.L.C., a Delaware limited liability company

•

GV 2019, L.P., a Delaware limited partnership

•

GV 2019 GP, L.P., a Delaware limited partnership

•

GV 2019 GP, L.L.C., a Delaware limited liability company

•

Verily Life Sciences LLC, a Delaware limited liability company

•

Alphabet Holdings LLC, a Delaware limited liability company

•

XXVI Holdings Inc., a Delaware corporation, and

•

Alphabet Inc., a Delaware corporation

Each of GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may be deemed to have sole power to vote or sole power to dispose of the securities owned directly by GV 2017, L.P.

Each of GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may be deemed to have sole power to vote or sole power to dispose of the securities owned directly by GV 2019, L.P.

Each of XXVI Holdings Inc. (the managing member of Verily Life Sciences LLC) and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may be deemed to have sole power to vote or sole power to dispose of the securities owned directly by Verily Life Sciences LLC.

ITEM 2(B).

ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE:

The address of the principal business office for each of the Reporting Persons is:

1600 Amphitheatre Parkway

Mountain View, CA 94043

Page 12 of 19

ITEM 2(C).

CITIZENSHIP:

GV 2017, L.P. is a Delaware limited partnership, GV 2017 GP, L.P. is a Delaware limited partnership, GV 2017 GP, L.L.C. is a Delaware limited liability company, GV 2019, L.P. is a Delaware limited partnership, GV 2019 GP, L.P. is a Delaware limited partnership, GV 2019 GP, L.L.C. is a Delaware limited liability company, Verily Life Sciences LLC is a Delaware limited liability company, Alphabet Holdings LLC is a Delaware limited liability company, XXVI Holdings Inc. is a Delaware corporation, and Alphabet Inc. is a Delaware corporation.

ITEM 2(D)/(E).

TITLE OF CLASS OF SECURITIES AND CUSIP NUMBER:

Common Stock, par value $0.001 per share

CUSIP # 92539P101

ITEM 3.

Not Applicable.

ITEM 4.

OWNERSHIP:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount beneficially owned:

See Row 9 of cover page for each Reporting Person.

(b)	Percent of Class:

See Row 11 of cover page for each Reporting Person.

(c)	Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote:

See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each Reporting Person.

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

Not Applicable.

Page 13 of 19

ITEM 6.

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Under certain circumstances set forth in the limited partnership agreement of GV 2017, L.P., the limited partnership agreement of GV 2019, L.P., the limited partnership agreement of GV 2017 GP, L.P., the limited partnership agreement of GV 2019 GP, L.P., the limited liability company agreement of GV 2017 GP, L.L.C., and the limited liability company agreement of GV 2019 GP, L.L.C., the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a general partner, limited partner, or member.

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

Not Applicable.

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

Not Applicable.

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP:

Not Applicable.

ITEM 10.

CERTIFICATION:

Not Applicable.

Page 14 of 19

SIGNATURES

After reasonable inquiry and to the best of her or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2022



GV 2017, L.P.
By: GV 2017 GP, L.P., its General Partner
By: GV 2017 GP, L.L.C., its General Partner
By: Alphabet Holdings LLC, its Sole Member

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Secretary

GV 2017 GP, L.P.
By: GV 2017 GP, L.L.C., its General Partner
By: Alphabet Holdings LLC, its Sole Member

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Secretary

GV 2017 GP, L.L.C
By: Alphabet Holdings LLC, its Sole Member

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Secretary

GV 2019, L.P.
By: GV 2019 GP, L.P., its General Partner
By: GV 2019 GP, L.L.C., its General Partner
By: Alphabet Holdings LLC, its Sole Member

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Secretary

GV 2019 GP, L.P.
By: GV 2019 GP, L.L.C., its General Partner
By: Alphabet Holdings LLC, its Sole Member

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Secretary

GV 2019 GP, L.L.C.
By: Alphabet Holdings LLC, its Sole Member

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Secretary

Verily Life Sciences LLC

By:		/s/ Duncan Welstead
Name:		Duncan Welstead
Title:		Finance Director

Alphabet Holdings LLC

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Secretary

Page 15 of 19


XXVI Holdings Inc.

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Assistant Secretary

Alphabet Inc.

By:		/s/ Kathryn W. Hall
Name:		Kathryn W. Hall
Title:		Assistant Secretary

Page 16 of 19

EXHIBIT INDEX


		Found on Sequentially
Exhibit		Numbered Page

Exhibit A: Agreement of Joint Filing		18

Page 17 of 19

SEC Form SC 13G filed by Verve Therapeutics Inc.